When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: Results of a WHO Think Tank

Current Opinion in HIV and AIDS

Volumn 12, Issue 4, 2017, Pages 414-422

  Vitoria, Marco ^a   Ford, Nathan ^a   Clayden, Polly ^b   Pozniak, Anton L ^c   Hill, Andrew M ^d  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b c o HIV i Base   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

antiretroviral treatment; drug drug interactions; HIV TB coinfection; pregnant women

Indexed keywords

ANTIRETROVIRUS AGENT; DOLUTEGRAVIR; EFAVIRENZ; INTEGRASE INHIBITOR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR ALAFENAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIRETROVIRAL THERAPY; BREAST FEEDING; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; MIXED INFECTION; MYOCARDITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; DEVELOPING COUNTRY; DRUG INTERACTION; PREGNANCY; SUPPLY AND DISTRIBUTION;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY;

EID: 85017456524     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000380     Document Type: Review

References (49)

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. 2nd ed. 2015. Available at: http://www. who. int/hiv/ pub/arv/arv-2016/en/. [Accessed 22 October 2016].
2. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults [2016] recommendations of the International Antiviral Society-USA Panel. JAMA 2016; 316: 191-210.
3. Department for Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2016. Available at: https://aidsinfo. nih. gov/contentfiles/lvguidelines/adultandadolescentgl. pdf. [Accessed 20 March 2017].
4. European AIDS Clinical SocietyGuidelines for HIV treatment. 2016. Available at: http://www. eacsociety. org/files/guidelines-8. 2-english. pdf. [Accessed 20 March 2017].
5. Venter F, Kaiser B, Pillay Y, et al. Cutting the cost of South African antiretroviral therapy using newer, safer drugs. South Afr Med J 2017; 107:28-30.
6. Clinton Health Access Initiative. ARV market report. The state of the antiretroviral drug market in low-and middle-income countries. 2015. Available at: http://www. clintonhealthaccess. org/content/uploads/2015/ 11/CHAI-ARV-Market-Report-2015-FINAL. pdf. [Accessed 25 August 2016].
7. Barnhart M, Shelton J. ARVs: The next generation. Going boldly together to new frontiers of HIV treatment. Glob Health Sci Prac 2015; 1:1-11.
8. Vitoria M, Hill AM, Ford N, et al. Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know J Int AIDS Soc 2016; 19:20504.
9. Zash R, Jacobson D, Diseko M, et al. Adverse birth outcomes differ by art regimen from conception in Botswana. CROI conference, 13-16 February 2017, Seattle, Washington. [Abstr 25].
10. Chi BH, FarhadM, Owor M et al. Antenatal Antiretroviral Therapy and Adverse Birth Outcomes: The PROMISE trial. Conference on Retroviruses and Opportunistic Infections February 2017. Seattle, WA, USA. Abstract 776.
11. Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-näve patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr 2015; 70:515-519.
12. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2015; 383:2222-2231.
13. STRIVING Study-switch from current treatment to dolutegravir. 2017. Available at: https://clinicaltrials. gov/ct2/show/results/NCT02105987?term= dolutegravir&rank=95. [Accessed 3 March 2017].
14. Llibre JM, et al. Phase III SWORD 1 & 2: Switch to DTGRPV maintains virologic suppression through 48 weeks. Presented at: Conference on Retroviruses and Opportunistic Infections; 13-16 February 2017; Seattle.
15. DAWNING Study: dolutegravir versus lopinavir/ritonavir as second-line treatment. Available at: https://clinicaltrials. gov/ct2/show/NCT02227238?term= dolutegravir&rank=110. [Accessed 3 March 2017]. N1/4612, Completion in August 2017.
16. Exclusion of pregnant women from HIV clinical trials. https://www. ncbi. nlm. nih. gov/pubmed/26361171. [Accessed 1 March 2017].
17. Lewis JM, Railton E, Riordan A, et al. Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing. AIDS 2016; 30:1313-1315.
18. Dolutegravir prescribing information. Available at: http://www. Accessdata. fda. gov/drugsatfda-docs/label/2013/204790lbl. pdf. [Accessed 20 March 2017].
19. IMPAACT 1026s: pharmacokinetic properties of antiretroviral and related drugs during pregnancy and postpartum. https://clinicaltrials. gov/ct2/show/ NCT00042289?term=dolutegravir&rank=131. [Accessed 3 March 2017]. N1/41700. End date October 2018.
20. DOLPHIN 1: dolutegravir in pregnant women. Available at: https://clinicaltrials. gov/ct2/show/NCT02245022?term=dolutegravir&rank=17. [Accessed3 March 2017]. N1/460.
21. NIH/NIAID VESTED Study: dolutegravir versus efavirenz in pregnant women. Available at: https://clinicaltrials. gov/ct2/show/NCT03048422?term=dolutegravirrank=109. [Accessed 3 March 2017]. N1/4549. End date May 2020.
22. ING200336, pharmacokinetic and safety study in pregnant women with human immuno virus infection. Available at: https://clinicaltrials. gov/ct2/ show/NCT02075593?term=dolutegravir&rank=129. [Accessed 3 March 2017]. N1/425. End date October 2021.
23. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013; 62:21-27.
24. Brooks K, Pau A, George J, et al. Early termination of a PK study between dolutegravir and weekly isoniazid/rifapentine. CROI Conference, 13-16 February 2017, Seattle, Washington [Abstr 409a].
25. INSPIRING Study: dolutegravir versus efavirenz in TB co-infection. Available at: https://clinicaltrials. gov/ct2/show/NCT02178592?term=dolutegravir& rank=89. [Accessed 3 March 2017]. N1/4125, Results end 2017.
26. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine-or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: A randomized clinical trial. Clin Infect Dis 2011; 53:716-724.
27. Rutherford GW, Horvath H. Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: A systematic review. PLoS One 2016; 11:e0162775.
28. Wijting I, et al. Integrase inhibitors are an independent risk factor for IRIS; an ATHENA-Cohort study. Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, abstract 731, 2017. Cohort study showing an association between integrase inhibitors and an increased risk of immune reconstitution inflammatory syndrome (IRIS).
29. Duterte M, et al. Initiation of ART based on integrase inhibitors increases the risk of IRIS. Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, abstract 732, 2017.
30. Spanish Immune Recovery study: dolutegravir versus darunavir/ritonavir in patients with CD4 counts >100/ml. Available at: https://clinicaltrials. gov/ct2/ show/NCT02337322?term=dolutegravir&rank=56. [Accessed 3 March 2017].
31. NAMSAL Study. Dolutegravir versus efavirenz in first-line treatment. Available at: https://clinicaltrials. gov/ct2/show/NCT02777229?term=dolutegravir& rank=58. [Accessed 3 March 2017].
32. ADVANCE Study: Dolutegravir versus efavirenz in first-line treatment. Available at: https://www. usaid. gov/sites/default/files/documents/1864/ ADVANCE-Trial-Landscape-508. pdf. [Date last accessed: 3 March 2017].
33. LLibre J, Esteve A, Miro J, et al. Discontinuation of DTG, EVG/c and RAL due to toxicity in a prospective cohort. CROI conference, February 13-16, Seattle, Washington. [Abstr 651].
34. de Boer M1, van den Berk G, van Holten N, et al. Intolerance of dolutegravir containing cART regimens in real life clinical practice. AIDS 2016. [Epub ahead of print]
35. Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 2017; 18:56-63.
36. Yagura H, Watanabe D, Nakauchi T, et al. Effect of dolutegravir plasma concentration on central nervous system side effects. CROI conference, February 13-16, Seattle, Washington. [Abstr 426].
37. Hsu A, Henegar C, Carpio F, et al. Psychiatric disorders observed in HIV patients using 6 common third agents in opera. CROI conference, February 13-16, Seattle, Washington. [Abstr 664].
38. Mahlab-Guri K, Asher I, Rosenberg-Bezalel S, et al. Two case reports of severe myocarditis associated with the initiation of dolutegravir treatment in HIV patients. Medicine 2016; 95:47.
39. Wang H, Lu X, Yang X, Xu N. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy. Medicine 2016; 95:e5146.
40. Ray A, Fordyce M, Hitchcock M. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res 2016; 125:63-70.
41. Tenofovir alafenamide prescribing information. Available at: http://www. Accessdata. fda. gov/drugsatfda-docs/label/2015/207561s000lbl. pdf. [Date last accessed: 20 March 2017].
42. Carey D, Puls R, Amin J, et al., ENCORE-1 Study Group. Efficacy and safety of efavirenz 400mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 2015; 15:793-802.
43. Dickinson L, Amin J, Else L, et al. Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400mg vs 600 mg) in treatment-näve HIV-infected patients: results of the ENCORE-1 study. Clin Pharm Therap 2015; 98:406-416.
44. Hill A, Khoo S, Back D, et al. The drug interaction between rifampicin and efiavirenz is time-dependent: systematic review of 12 pharmacokinetic studies. World AIDS Conference, Melbourne, Australia, July 2014 [Abstr MOPE040].
45. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482-1483.
46. Paton N, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371:234-247.
47. Amin J, Boyd MA, Kumarasamy N, et al. Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection. PLoS One 2015; 10:e0118228.
48. D2EFT Study. Dolutegravir plus darunavir/ritonavir as a second-line treatment. Available at: https://clinicaltrials. gov/ct2/show/NCT03017872?term= dolutegravir&rank=45. [Accessed 3 March 2017]. N1/4610.
49. World Health Organisation. Hepatitis B factsheet. Available at: http:// www. who. int/mediacentre/factsheets/fs204/en/. [Accessed 20 March 2017].